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Maturity-onset diabetes of the young (MODY) classically describes dominantly inherited
forms of monogenic diabetes diagnosed before 25 years of age due to pancreatic
β-cell dysfunction. In contrast, mutations in certain MODY genes can also present
with transient or persistent hyperinsulinemic hypoglycemia in newborn infants, reflecting
instead β-cell dysregulation. Of the MODY genes described to date, only hepatocyte
nuclear factor-4-alpha (HNF4A; MODY1) and hepatocyte nuclear factor-1-alpha (HNF1A;
MODY3) mutations may result in a biphasic phenotype of hypoglycemia in early life
and hyperglycemia in later life. We report a family with a novel HNF4A mutation with
diverse phenotypic presentations of glucose dysregulation. The proband was a term,
appropriate-for-gestational age male infant with symptomatic hypoglycemia on day 3
of life needing high glucose infusion rate to maintain normoglycemia. He was born
to a non-obese and non-diabetic mother. Glucose regulation was optimized using
diazoxide upon confirmation of hyperinsulinism. Cascade genetic screening identified
the same mutation in his father and elder sister, but mother was negative. Father
was diagnosed with Type 1 diabetes at 15 years of age that required insulin therapy.
Proband’s elder sister, born at term appropriate for gestational age, presented with
transient neonatal hypoglycemia needing parenteral glucose infusion for a week followed
by spontaneous resolution. The paternal grandparents were negative for this mutation,
confirming a paternal de novo mutation and autosomal dominant inheritance in this
family. This pedigree suggests that the presence of early-onset paternal diabetes
should prompt molecular testing in infants presenting in the newborn period with
diazoxide-responsive hyperinsulinemic hypoglycemia, even in the absence of maternal
diabetes and macrosomia.
Keywords: maturity-onset diabetes mellitus, hepatocyte nuclear factor 4-alpha, hepatocyte nuclear
factor−1- alpha, hyperinsulinemic hypoglycemia of infancy, congenital hyperinsulinism, diazoxide
Chandran et al. HNF4A Mutation With Multiple Phenotypes
INTRODUCTION
Maturity-onset diabetes of the young (MODY) is an acronym
used to describe dominantly inherited forms of monogenic
diabetes diagnosed before 25 years of age (1). MODY gene
mutations have been described with clinically heterogeneous
phenotypes (2). Among these, only HNF4A (MODY1) and
HNF1A (MODY3) mutations on chromosomes 12 and 20
respectively, may result in a biphasic phenotype (3). HNF4A
is an orphan receptor protein expressed in the liver, kidney,
gut, and pancreatic β-cells (4). Mutations in HNF4A may
lead to biphasic presentations, characterized by transient or
persistent HH in infants, and diabetes in young adults. HNF4A
mutations are a less common cause of MODY (10%) than
glucokinase (GCK) (30–50%) and HNF1A (30–50%). Among
infants with HNF4A mutations, 56% are macrosomic and
15% encounter neonatal hypoglycemia (5). The prevalence of
neonatal hypoglycemia is similar regardless of parental HNF4A
inheritance and persistent hypoglycemia is independent of
gestational glucose control (6). Hyperinsulinemic hypoglycemia
(HH) is characterized by inappropriate insulin secretion while
hypoglycemic and the need for high glucose infusion rate (GIR)
requirements (>8 mg/kg/min) to maintain normoglycemia
(3.5–5.9 mmol/L) in newborn infants beyond 48 h of life.
HH infants have inappropriate insulin and/or C-peptide levels
despite the presence of hypoglycemia, hypoketonemia and
hypofattyacidemia. HH is linked to mutations in at least
eight genes (ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1,
HNF4A, HNF1A) that alter β-cell function (7). Unlike the
majority of mutations involving the KATP channel, HNF4A
mutations causing HH respond well to diazoxide (8). We
present a family with a novel HNF4A mutation identified from
a proband presenting with symptomatic hypoglycemia. The
family members were found to have contrasting phenotypic
presentations of glucose dysregulation in spite of having the same
mutation. We present this pedigree to demonstrate that a history
of paternal diabetes is as important as a history of maternal
diabetes, and relevant in pediatric history-taking when managing
infants at-risk of hypoglycemia.
CASE PRESENTATION
Pedigree Report
A healthy male infant weighing 3,592 gm was born to non-
consanguineous parents at 37+5 weeks gestation and discharged
uneventfully on day 2 of life. Both parents are of Malay ethnicity.
Maternal health during pregnancy and oral glucose tolerance
test results were normal. There was no maternal family history
of diabetes. On day 3 of life, this infant was admitted for
treatment of neonatal jaundice. While on phototherapy he was
noted to be apneic and cyanosed with low plasma glucose (1.8
mmol/L). Resuscitation involved mini bolus intravenous 10%
dextrose and continuous glucose infusion. As the response was
inadequate, GIR was graded up to 16 mg/kg/min before glucose
levels normalized.
Physical examination of the infant was unremarkable. Upon
reduction of GIR in a controlled setting, critical blood tests
were obtained that showed detectable C- peptide [1.7mcg/L]
and insulin [10.4 mU/L] when plasma glucose was 1.6 mmol/L.
Along with suppressed blood ketones of 0.2 mmol/L, these
indicate inappropriate insulin production during hypoglycaemia,
which fulfilled the diagnostic criteria for HH. Serum cortisol
was 494 nmol/L and GH level was 13.4 ug/L, showing adequate
pituitary response. Septic and inborn error of metabolism screens
were negative. On day 7 of life, he was started on diazoxide,
5 mg/kg/day in divided doses, with normoglycemia achieved
after titrating diazoxide up to 10 mg/kg/day on day 19 of
life. Hydrochlorothiazide was added to counteract the salt and
water retaining side effects of diazoxide. Thereafter, his GIR was
weaned over 5 days and he remained normoglycemic on full oral
feeds. Before discharge while on diazoxide, he passed a 6-h safety
fast study, to reassure of his ability to maintain glucose levels
during inadvertent fasting periods at home. Glucose monitoring
continued at home. The absolute diazoxide dose was maintained,
allowing weight-based reduction of the dose toward 24 months
of age. At 36 months, diazoxide was stopped and he underwent
and passed a resolution fasting study. Growth and neurocognitive
development are currently appropriate for age.
Genetic testing for hyperinsulinism was performed at Exeter,
UK. Analysis of coding and flanking intronic regions of the
KCNJ11, ABCC8, and HNF4A genes by Sanger sequencing
was done. Both KCNJ11 and ABCC8 genes were normal. A
novel heterozygous HNF4A missense mutation, p.Asp345Tyr
(c.1033G>T) was identified. Cascade family screening identified
the same HNF4Amutation in his father and elder sister; whereas
his mother and paternal grandparents were negative (Figure 1).
This confirmed that the proband’s father has a de novomutation,
consistent with MODY rather than type 1 diabetes.
The proband’s father was diagnosed with diabetes at age
15 years and treated with insulin. He was obese from early
childhood, even though there was no history of diabetes in
his parents or siblings. Details of initial management prior to
his transfer to tertiary diabetes care are unavailable. At age 33
years, his glycated hemoglobin (HbA1c) was 12%, fasting glucose
18.3 mmol/L, C-peptide 270 pmol/L (364-1655), glutamic acid
decarboxylase (GAD) autoantibody and islet-cell autoantibody
tested negative. Diabetes control was suboptimal due to poor
adherence. On Metformin 850mg twice daiy (BD) and basal-
bolus insulin therapy, HbA1c ranged from 6.9 to 10% over
the next 5 years. At age 38 years, he was reassessed following
his son’s genetic diagnosis. While on Metformin 850mg BD,
subcutaneous (SC) Glargine 16u BD and SC Glulisine 10–14u
thrice daily (TDS), HbA1c was 9%, fasting glucose 16.5 mmol/L
and C-peptide 481 pmol/L. He measured 1.54m, weighed 86 kg,
giving a BMI of 36.3 kg/m2. Given his reasonable insulin reserve,
sulphonylurea therapy was initiated to determine if insulin
doses could be reduced without compromising glucose control.
Ambulatory glucose profiles were conducted over a 2-week
period—in the first week, he was on his usual treatment regimen
while in second week, sulphonylurea was added (Figure 2). He
responded to up-titrated doses of Glibenclamide with reduction
of basal insulin from 32 to 8 units daily, while maintaining similar
glucose profiles. Over these 2 weeks, the composite ambulatory
glucose profile showed average glucose of 9.6 mmol/L, giving
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FIGURE 1 | HNF4A family pedigree. Circles (females) and squares (males). Arrow marks the Proband. Filled symbol indicates MODY (father); unfilled symbol indicates
no history of glucose dysregulation. Diagonal hatching denotes persistent HH (proband). Transverse hatching indicates transient hypoglycemia (sister). M/N =
heterozygous HNF4A genotype; N/N = normal genotype.
an estimated HbA1c of 7.7%. His current medication doses are
Glibenclamide 7.5mg BD, Metformin 850mg BD, SC Glargine
8 units every night (ON) and SC Glulisine 10u BD. After
glibenclamide was added and the basal insulin dose was reduced,
there was improvement in his fasting glucose levels from 11-
13 mmol/L to 5-6.4 mmol/L. Despite subsequent increments in
sulphonylureas, he required prandial (albeit decreased) doses
of glulisine for persistent postprandial hyperglycemia. His total
daily insulin requirements decreased from 1 to 0.5 u/kg/d.
The incomplete response to sulphonylureas was likely due to
progressive defect in beta cell β-cell dysfunction after having had
diabetes for 23 years. His most recent BMI was 36.4 kg/m2.
The proband’s 8 year old sister who was born term,
appropriate for gestational age (birth weight, 2835 g) had
transient hypoglycemia during neonatal period. Work up for
sepsis and inborn error of metabolism screen were negative.
However, her phenotype was mild and she required intravenous
dextrose (highest GIR 7.6 mg/kg/min on day 4 of life), before
gradual increase in feeds normalized her blood glucose levels
by day 7 of life. She has appropriate growth and remains in a
mainstream school (Figure 3).
Family’s Perspective
Upon receiving news of the genetic diagnosis, the proband’s
father was hopeful for better control with reduced insulin.
Although his endocrinologist was able to use this information
to adjust his treatment regimen, he experienced difficulty
making lifestyle changes which limited his glucose control and
prevented further reduction of his medications. The proband’s
mother was more concerned about the implications of the
diagnosis on her children. She was particularly happy that
the proband did not require long-term Diazoxide therapy,
although she was concerned of the risk of diabetes in both her
children. The proband’s paternal grandparents expressed that
the exact diagnosis makes them aware of the risk of childhood-
onset diabetes. They clearly indicated their hope for their
grandchildren to remain healthy and not to develop obesity and
childhood-onset diabetes like their son (the proband’s father) did.
DISCUSSION
We describe a pedigree where a heterozygous novel HNF4A
mutation was identified in 3 individuals of a 2 generation
family. Each of these individuals were phenotypically distinct—
the proband had persistent HH, his sister had transient
hypoglycemia, while his father had juvenile-onset MODY.
The paternal grandparents tested negative, confirming
a spontaneous de novo mutation, followed by dominant
inheritance. Identification of the underlying genetic etiology
allowed for a molecular diagnosis of the proband, clarified the
paternal phenotype as MODY instead of type 1 diabetes and
facilitated his improved diabetes management.
Up to 80% cases of diabetes due to MODY gene mutations are
misclassified as type 1 or type 2 diabetes, leading to inappropriate
medical therapy (9). The diagnosis of MODY requires molecular
confirmation (10). In retrospect, precise molecular diagnosis
of the diabetes in the proband’s father would have permitted
close fetal monitoring for macrosomia and appropriate postnatal
glucose surveillance. Mutations in HNF4A are reported to be
highly penetrant with 50% of carriers developing diabetes by
age 30 years, whereas 60% with HNF1A mutations present by
25 years (11). The father of the proband was diagnosed with
diabetes at age 15 years, expressing the highly penetrant nature
of this novel HNF4Amutation. Infants who inherit HNF4A have
significantly increased birth weight, with more than half having
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FIGURE 2 | Continuous blood glucose patterns of the proband’s father, capturing his daily glucose variability over 2 weeks, while he was on Metformin 850mg twice
daily, Glargine 16 units twice daily and Glulisine 10–14 units thrice daily (first week); and demonstrating improved fasting glucose levels despite progressive reduction
in Glargine doses after Glibenclamide was progressively introduced (second week).
macrosomia. The risk of macrosomia is higher in maternally-
inherited mutations (64%) compared to paternal inheritance
(46%), due to the additional effect of hyperglycemic intrauterine
milieu (6). The paternal inheritance pattern in this pedigree may
explain the absence of macrosomia in both his offsprings.
HNF4A mutations are the third most common genetic
cause of diazoxide-responsive HH, (8) however the mechanism
by which these mutations cause insulin excess in fetal and
neonatal life and insulin deficiency later in life is unclear.
Heterozygous loss-of-function mutations in HNF4A may cause
either transient or persistent HH (6, 12). Current evidence
supports a reduction in expression of inward rectifying
potassium channel subunit (Kir 6.2) and/or reduction in
the levels of peroxisome proliferator-activated receptor alpha
(PPARα), causing inappropriate insulin secretion and resulting
in HH in newborn period (13, 14). Low levels of PPARα
have been reported in HNF4A deficient β-cells, resulting in
the accumulation of lipids and thereby increasing cytosolic
long-chain acyl-CoA levels, signaling insulin release. Long-term
exposure of β-cells to elevated concentrations of fatty acids causes
β-cell dysfunction leading to diabetes (15). Other suggested
theories for the dual phenotype in HNF4A mutations include
variance in HNF4A dependent temporal gene expression, β-
cell exhaustion from hypersecretion in fetal life and infancy
and malfunction of transcription factors that sustain β-cell
function in pancreatic islets (7, 16, 17). MODY responds
well to low-dose sulfonylurea, maintaining the glucose profile
even after 3 decades (16, 18). In individuals with a HNF4A
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FIGURE 3 | Timeline depicting the three phenotypes of this pedigree.
mutation, as the β-cell dysfunction is progressive with age,
insulin treatment may eventually be required. If the proband’s
father had received an early genetic diagnosis, he may have
benefitted from oral sulfonylurea instead of insulin. Secondary
sulphonylurea failure has been described to occur in 3 to
25 years following diagnosis/treatment in transcription factor
linked-MODY patients (19). Unlike GCK mutations, patients
with diabetes due to HNF4A and HNF1A mutations are
at increased risk of micro and macrovascular complications,
(6, 9, 18, 20) and therefore require early and sustained
glucose control.
Diazoxide remains the first line of medical treatment for HH.
Diazoxide response in HH due to aHNF4Amutation is adequate
but the treatment period may vary from months to years (9). In
this proband with a novel HNF4A mutation, glucose levels were
controlled with moderate doses of diazoxide weaned over 3 years.
Following cessation of therapy, resolution of HH was confirmed
with a fasting study. As there is potential of developing MODY,
glucose tolerance testing is planned for the proband and his sister.
The strength of this case study lies in the full phenotypic
characterization of the proband and cascade genetic testing in his
family. However, type 1 diabetesmanagement details of the father
are unavailable prior to the proband’s diagnosis. The proband’s
sister was not evaluated for hyperinsulinism as she did not meet
the criteria for HH.
In conclusion, we present a family with a novel HNF4A
mutation having 3 phenotypic presentations across 2 generations.
This case pedigree supports HNF4A gene sequencing for infants
presenting in the newborn period with diazoxide-responsive
HH and paternal diabetes, even in the absence of maternal pre
or gestational diabetes and fetal macrosomia. Those with prior
molecular diagnosis of HNF4A mutation should be monitored
for early diagnosis of sulfonylurea-sensitive diabetes, to allow
earlier intervention and treatment. Overall, an early molecular
diagnosis of HNF4AMODY can guide a change in therapy from
insulin to sulfonylurea, improving the lifestyle and quality of life
for both patients and their families.
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